Table 6.

GEE regression analysis for the number of embryos available to transfer.

Independent variable	POSEIDON group 1			POSEIDON group 2			POSEIDON group 3			POSEIDON group 4
	IRR	95% CI	p-value	IRR	95% CI	p-value	IRR	95% CI	p-value	IRR	95% CI	p-value
GH supplementation
Non-GH	_	_		_	_		_	_		_	_
GH	2.33	1.96–2.77	<0.001*	1.57	1.26–1.95	<0.001*	2.06	1.51–2.82	<0.001*	1.31	1.02–1.69	0.033*
Age	1.00	0.96–1.04	0.993	0.98	0.94–1.02	0.369	1.02	0.96–1.08	0.539	0.99	0.95–1.04	0.796
BMI	0.98	0.95–1.01	0.173	0.97	0.93–1.01	0.135	1.05	1.00–1.10	0.037*	0.98	0.93–1.04	0.500
AMH	1.06	1.01–1.11	0.011*	0.94	0.86–1.03	0.213	2.29	1.27–4.13	0.006*	0.97	0.59–1.59	0.899
FSH	1.01	0.95–1.07	0.771	0.95	0.89–1.02	0.157	0.99	0.93–1.04	0.599	0.99	0.95–1.03	0.661
AFC	0.98	0.96–1.00	0.118	1.02	0.99–1.06	0.178	1.01	0.94–1.08	0.806	1.02	0.95–1.08	0.654
COH protocol
GnRH antagonist	_	_		_	_		_	_		_	_
GnRH agonist long	1.15	0.94–1.41	0.166	1.23	0.94–1.61	0.130	1.01	0.69–1.48	0.955	1.46	1.02–2.11	0.041*
GnRH agonist ultra-long	0.91	0.66–1.24	0.551	1.01	0.67–1.51	0.971	0.88	0.55–1.41	0.597	1.30	0.82–2.07	0.260
GnRH agonist short	1.24	0.97–1.60	0.090	1.18	0.88–1.58	0.261	0.95	0.64–1.40	0.799	1.02	0.75–1.39	0.915
Duration of Gn	1.04	0.98–1.10	0.169	1.05	0.97–1.13	0.235	1.08	0.98–1.17	0.108	1.05	0.96–1.15	0.284
Gn dose (per 100 IU)	0.99	0.98–1.00	0.150	0.99	0.97–1.00	0.130	0.99	0.97–1.00	0.139	1.00	1.00–1.00	0.083

GH, growth hormone; BMI, body mass index; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; AFC, antral follicle count; COH, controlled ovarian hyperstimulation; GnRH, gonadotropin-releasing hormone; Gn, gonadotropin.

In bold: The values associated with GH.

*indicates statistical significances of p < 0.05.